Genotyping a Deletion Polymorphism in the TRY6 Gene and Breast Cancer Risk
Author Information
Author(s): Kerstin Wagner, Ewa Grzybowska, Dorota Butkiewicz, Jolanta Pamula-Pilat, Wioletta Pekala, Karolina Tecza, Kari Hemminki, Asta Försti
Primary Institution: German Cancer Research Center (DKFZ)
Hypothesis
Is the TRY6 deletion polymorphism associated with breast cancer risk?
Conclusion
The study found no association between the TRY6 deletion polymorphism and breast cancer risk.
Supporting Evidence
- The deletion polymorphism was genotyped using a high-throughput fluorescent fragment analysis.
- No differences in allele and genotype frequencies were found between breast cancer cases and controls.
- The study had sufficient power to detect an odds ratio of 0.6.
Takeaway
The researchers looked at a gene deletion to see if it affects breast cancer risk, but they found it doesn't.
Methodology
A case-control study was performed using a triplex PCR for genotyping the deletion and TaqMan allelic discrimination for SNP analysis.
Limitations
The study may not have detected a major to moderate effect of the TRY6 deletion on breast cancer risk due to the nature of the gene being a pseudogene.
Participant Demographics
397 Polish familial and early age breast cancer cases and 454 matched controls.
Statistical Information
Confidence Interval
95% CI 0.71–1.56
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website